When synergized with a PD-L1 small molecule inhibitor, HMC achieved over 70% tumor growth inhibition in orthotopic and subcutaneous mouse models, with enhanced IFN-γ+ CD8+ T cell accumulation, demonstrating superior in vivo sono-immunotherapy via ROS-mediated mechanisms (50). The gene discussed is CD8A; the disease is neoplasm.